Elanco Animal Health Incorporated (NYSE:ELAN) Shares Purchased by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund increased its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 38.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 376,262 shares of the company’s stock after buying an additional 103,692 shares during the quarter. Illinois Municipal Retirement Fund owned about 0.08% of Elanco Animal Health worth $4,557,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the business. JPMorgan Chase & Co. lifted its holdings in shares of Elanco Animal Health by 76.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 10,057,656 shares of the company’s stock worth $147,747,000 after acquiring an additional 4,361,799 shares during the period. State Street Corp increased its position in Elanco Animal Health by 2.6% during the third quarter. State Street Corp now owns 9,912,693 shares of the company’s stock worth $145,617,000 after purchasing an additional 255,084 shares during the last quarter. Geode Capital Management LLC raised its stake in Elanco Animal Health by 0.8% during the third quarter. Geode Capital Management LLC now owns 7,868,675 shares of the company’s stock worth $115,623,000 after purchasing an additional 65,303 shares during the period. The Manufacturers Life Insurance Company raised its stake in Elanco Animal Health by 6.6% during the third quarter. The Manufacturers Life Insurance Company now owns 6,385,467 shares of the company’s stock worth $93,803,000 after purchasing an additional 394,921 shares during the period. Finally, Wellington Management Group LLP boosted its holdings in shares of Elanco Animal Health by 19.2% in the 3rd quarter. Wellington Management Group LLP now owns 4,007,805 shares of the company’s stock valued at $58,875,000 after purchasing an additional 646,522 shares during the last quarter. 97.48% of the stock is owned by institutional investors and hedge funds.

Elanco Animal Health Stock Performance

Shares of NYSE:ELAN opened at $11.15 on Thursday. The business’s 50-day simple moving average is $11.74 and its 200 day simple moving average is $13.06. The company has a market cap of $5.51 billion, a P/E ratio of 27.88, a PEG ratio of 2.50 and a beta of 1.42. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. Elanco Animal Health Incorporated has a one year low of $10.20 and a one year high of $18.80.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Tuesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01). The firm had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.01 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company’s revenue for the quarter was down 1.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.08 EPS. On average, sell-side analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently commented on ELAN. Morgan Stanley dropped their price objective on Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating for the company in a report on Wednesday. Leerink Partnrs upgraded Elanco Animal Health to a “hold” rating in a report on Monday, December 2nd. UBS Group reduced their price objective on Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating on the stock in a research note on Wednesday. Stifel Nicolaus dropped their target price on shares of Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Friday, February 21st. Finally, Leerink Partners assumed coverage on shares of Elanco Animal Health in a research report on Monday, December 2nd. They set a “market perform” rating and a $14.00 price target on the stock. One analyst has rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $15.57.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.